Article

Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancer

2025-07-08

Abstract excerpt

<title>Abstract</title> <p>Background Elderly Chinese patients with advanced non-small cell lung cancer (NSCLC) often refuse chemotherapy due to the risk of intolerable grade 3–4 adverse events. This study aimed to evaluate the efficacy and safety of nivolumab plus ipilimumab in elderly patients with advanced NSCLC. Methods We retrospectively analyzed data from elderly patients with advanced NSCLC treated with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8a76ec0a-b3c5-50bd-b136-f3823761cf55
DOI: 10.21203/rs.3.rs-6796417/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancerDOI 10.21203/rs.3.rs-6796417/v1Read

Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity Read

A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancerSemantic proximity Read

Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity Read

Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity Read

Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity Read

Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity Read

Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and OlderSemantic proximity Read

[China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)].Semantic proximity Read

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read

Real-world study of first-line therapy with aumolertinib for elderly patients with non‑small cell lung cancer harboring EGFR mutationSemantic proximity Read

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity Read

Sugemalimab: First Approval.Semantic proximity Read